Fusion Pharmaceuticals Inc logo

FUSN

Fusion Pharmaceuticals Inc

$2.06

Earnings Summary

Revenue
$0.59Mn
Net Profits
$-19.91Mn
Net Profit Margins
-3403.25%

Highlights

Revenue:

Fusion Pharmaceuticals Inc’s revenue jumped +Inf% since last year same period to $0.59Mn in the Q1 2022. On a quarterly growth basis, Fusion Pharmaceuticals Inc has generated -1.52% fall in its revenue since last 3-months.

Net Profits:

Fusion Pharmaceuticals Inc’s net profit fell -13.58% since last year same period to $-19.91Mn in the Q1 2022. On a quarterly growth basis, Fusion Pharmaceuticals Inc has generated -15.51% fall in its net profits since last 3-months.

Net Profit Margins:

Fusion Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -3403.25% in the Q1 2022. On a quarterly growth basis, Fusion Pharmaceuticals Inc has generated -17.29% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Fusion Pharmaceuticals Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.53
EPS Estimate Current Year
-0.53

Highlights

EPS Estimate Current Quarter:

Fusion Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.53 - a -10.42% fall from last quarter’s estimates.

EPS Estimate Current Year:

Fusion Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.53.

Key Ratios

Key ratios of the Fusion Pharmaceuticals Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.46
Return on Assets (ROA)
-0.19
Return on Equity (ROE)
-0.33
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Fusion Pharmaceuticals Inc’s earning per share (EPS) fell -9.52% since last year same period to -0.46 in the Q1 2022. This indicates that the Fusion Pharmaceuticals Inc has generated -9.52% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Fusion Pharmaceuticals Inc’s return on assets (ROA) stands at -0.19.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Fusion Pharmaceuticals Inc’s return on equity (ROE) stands at -0.33.

Dividend Per Share (DPS):

Fusion Pharmaceuticals Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-10
-0.48
-0.46
4.17%

Company Information

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. The Company is advancing a pipeline of targeted radiopharmaceutical cancer therapies for a broad array of tumor types based upon its proprietary platform technology.

Organisation
Fusion Pharmaceuticals Inc
Headquarters
270 Longwood Road South, Hamilton, ON, Canada, L8P 0A6
Employees
61
Industry
Health Technology